Company news
Voyager Therapeutics, Inc. (NASDAQ:VYGR) news
Every Voyager Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
August 3, 2023
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
July 27, 2023
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
July 10, 2023
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
May 18, 2023
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
May 9, 2023
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors
May 9, 2023
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 2, 2023
Voyager Therapeutics Announces First Quarter 2023 Conference Call and Webcast
May 2, 2023
Voyager Therapeutics Presents New Data Supporting Tau Antibody Program for Alzheimer’s Disease and GBA1 Gene Therapy Program for Parkinson’s Disease at the AD/PD™ Conference
March 28, 2023
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
March 7, 2023
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
March 6, 2023
Voyager Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
February 28, 2023
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
December 14, 2022
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
November 8, 2022
Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
November 1, 2022
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families
October 11, 2022
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
October 4, 2022
Voyager Therapeutics Announces Data Presentations at the 29th Annual Congress of the European Society of Gene & Cell Therapy
October 3, 2022
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
September 7, 2022
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
August 4, 2022
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
August 3, 2022
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
July 28, 2022
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
May 19, 2022
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
May 4, 2022
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
May 3, 2022
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
March 22, 2022
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
March 8, 2022
Alfred W. Sandrock, Jr., M.D., Ph.D. Appointed to Voyager Therapeutics’ Board of Directors and Newly Formed Executive Committee
February 3, 2022
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
November 19, 2021
Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results
November 2, 2021
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
October 20, 2021
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
October 6, 2021
Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies
August 9, 2021
Voyager Therapeutics Announces Strategic Shift and Leadership Transitions
May 19, 2021
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
May 11, 2021
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
May 10, 2021
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
April 28, 2021
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
April 26, 2021
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
February 25, 2021
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
February 18, 2021
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
November 9, 2020
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
October 12, 2020
Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors
September 15, 2020
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
September 14, 2020
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
August 10, 2020
Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
May 6, 2020
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting
April 29, 2020
Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial
April 3, 2020
Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference
March 9, 2020
Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
March 3, 2020